Impaired carboxylation of osteocalcin in warfarin-treated patients.
The total circulating osteocalcin and ratio of inactive (noncarboxylated; GLU) to active (carboxylated; GLA) form of circulating osteocalcin were measured in patients receiving long term warfarin treatment (n = 20), age-matched control patients not receiving warfarin treatment (n = 10), and normal subjects before and after the administration of 30 mg warfarin (n = 7). There was no significant difference in the total osteocalcin concentrations between the control patients and the patients receiving long term warfarin treatment, and it did not significantly change after warfarin ingestion in the normal subjects. The GLU/GLA ratio was significantly increased (P less than 0.002) in the patients receiving long term warfarin treatment compared with that in the control patients. There was a significant increase (P less than 0.01) in the GLU/GLA ratio after warfarin ingestion in the normal subjects. This study demonstrates that osteocalcin carboxylation in humans is a vitamin K-dependent process and that circulating osteocalcin is structurally altered by warfarin administration. This finding has pathophysiological implications for the fetal warfarin embryopathy syndrome, bone disease associated with chronic liver diseases, and possibly for osteoporosis, in which vitamin K deficiency has been implicated.
D015055:1-Carboxyglutamic Acid / Q000097:blood*; D000328:Adult; D000368:Aged; D002135:Calcium-Binding Proteins / Q000097:blood*; D005260:Female; D005971:Glutamates / Q000097:blood; D018698:Glutamic Acid; D006801:Humans; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin; D014812:Vitamin K / Q000097:blood*; D014859:Warfarin / Q000494:pharmacology*
D002135:Calcium-Binding Proteins; D005971:Glutamates; D015675:Osteocalcin; D014812:Vitamin K; D018698:Glutamic Acid; D015055:1-Carboxyglutamic Acid; D014859:Warfarin